SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Hepion Pharmaceuticals, Inc. HEPA OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Hepion Pharmaceuticals, Inc. (HEPA) is a Biotechnology company in the Healthcare sector, currently trading at $0.05. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is HEPA = $70 (+145733.3% upside).

Net income is $8M (loss), growing at +31.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $54,066 against $3M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 10.25 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $3M.

Analyst outlook: 1 / 3 analysts rate HEPA as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$70.00

▲ 145733.33% Upside

Average Price Target

The 12-month price target for Hepion Pharmaceuticals, Inc. is $70.00.

HEPA SharesGrow Score Overview

69/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 52/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HEPA

HEPA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $70, implying +145733.3% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

HEPA: +0%/yr revenue is, +31.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet HEPA: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 10.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

HEPA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 3 analysts rate HEPA as buy (33%). Analyst consensus target is $70 (+145733.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.033-0.746

Volume6

Avg Volume (30D)12.48K

Market Cap$557.78K

Beta (1Y)1.61

Share Statistics

EPS (TTM)-0.88

Shares Outstanding$9.41M

IPO Date2014-02-10

Employees22

CEOVincent LoPriore

Financial Highlights & Ratios

EBITDA$-8.25M

Net Income$-8.28M

Operating Income$-4.16M

Total Cash$1.83M

Total Debt$54.07K

Net Debt$-1.77M

Total Assets$3.07M

Price / Earnings (P/E)-0.1

Analyst Forecast

1Y Price Target$70.00

Target High$70.00

Target Low$70.00

Upside+145,733.3%

Rating ConsensusHold

Analysts Covering3

Buy 33% Hold 67% Sell 0%

Price Target Summary

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS4268974015

Price Chart

HEPA

Hepion Pharmaceuticals, Inc. ↗ · Other OTC

Healthcare • Biotechnology

0.03 52WK RANGE 0.75

People Also View

Zura Bio Limited

Elevation Oncology, Inc.

Enveric Biosciences, Inc.

Ocean Biomedical, Inc.

eFFECTOR Therapeutics, Inc.

Eli Lilly and Company

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message